SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...

Last month, “historic positive results” from uniQure’s gene therapy snapped the Huntington’s community out of years of failure. As the biotech prepares to submit for FDA approval, BioSpace looks at ...

Austedo (deutetrabenazine) and Ingrezza (valbenazine) are prescription drugs used to treat tardive dyskinesia and chorea associated with Huntington’s disease. Austedo and Ingrezza are not available as ...

Topline data showed that an investigational gene therapy slowed Huntington's disease progression and met its primary endpoint in a pivotal trial, uniQure Biopharma announced Wednesday. A high-dose ...

Preliminary results from a small trial offer the clearest evidence yet that the brain disease’s progression can be slowed. A one-time gene therapy can markedly slow the progression of Huntington’s ...

A new medical trial showed promising results as scientists seek a breakthrough to treat Huntington's disease, according to research team based in the United Kingdom. The clinical drug trial by ...